Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 6;23(7):1654. doi: 10.3390/molecules23071654

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of DBTD on the mTOR pathway and triglyceride (TG) metabolism. Cells were treated with 0.1 μmol/L rapamycin (Rapa) for 6 h, 0.2 μmol/L DBTD for 24 h, and pretreated with 0.1 μmol/L Rapa for 6 h followed by a 24 h treatment of 0.2 μmol/L DBTD, respectively. The control group (Con) was incubated with culture media only. (A) measurement of intracellular TG content. (B) Expressions analysis of SREBP1C, SCD1, FASN, GPAT1, PPARα, ACOX1, CPT1, and CYP4A11 by RT-PCR. (C) Protein analysis by immunoblot, (a) representative bands of relevant proteins. Protein levels of (b) p-S6K1 (Thr421), (c) SREBP1C, (d) SCD1, (e) FASN, (f) PPARα, and (g) ACOX1. Quantities are expressed as relative intensities against GAPDH except for p-S6K1 (Thr421), which was against S6K1. Data are presented as the mean ± SD of three experiments. * p < 0.05 and ** p < 0.01 versus control. # p < 0.05 and ## p < 0.01 versus Rapa group.